Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791157 | 1.00 | CRBN (0.71) | CRBNCSNK1A1MAP1LC3BIKZF1BRD4 | |
| SCHEMBL23565612 | 0.91 | CRBN (0.69) | CRBN | |
| SCHEMBL25123250 | 0.91 | CRBN (0.71) | CRBNCSNK1A1MAP1LC3BIKZF1 | |
| SCHEMBL23565611 | 0.90 | CRBN (0.65) | CRBNIKZF1BRD4TNFIL1B | |
| SCHEMBL23565610 | 0.87 | CRBN (0.70) | CRBNCSNK1A1MAP1LC3BIKZF1BRD4 | |
| SCHEMBL23564835 | 0.85 | CRBN (0.66) | CRBNCSNK1A1IKZF1BRD4TNF | |
| SCHEMBL476917 | 0.83 | CRBN (1.00) | CRBNCSNK1A1IKZF1BRD4TNF | |
| SCHEMBL19556664 | 0.83 | CRBN (1.00) | CRBNCSNK1A1IKZF1BRD4TNF | |
| SCHEMBL19556665 | 0.83 | CRBN (1.00) | CRBNCSNK1A1IKZF1BRD4TNF | |
| SCHEMBL27097754 | 0.83 | CRBN (1.00) | CRBNCSNK1A1IKZF1BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4076464-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-115348872-A | Bifunctional agents for protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-4076464-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076530-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021126974-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | CRBN 1/4885CSNK1A1 565/4885MAP1LC3B 360/4885 |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | MDM2, SUMO2, MYCBP2 | CRBN 218/4885CSNK1A1 1642/4885MAP1LC3B 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.